HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
Abstract
Authors
R. Chu R. Tudor D.S. Choi O. Wong KKW Chan N.B. Leighl BCF Chan P.C. Coyte H.H. Rebecca